Agios Pharmaceuticals, Inc. (AGIO)
Agios Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, MA, US. The stock last traded at $33.49, up 2.46% on the session, giving a market capitalisation of $2.00B. On trailing twelve-month figures it carries a trailing P/E of -4.78, a net margin of -418.2%. Its beta of 0.59 implies it has historically moved less than the broad market.
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Agios Pharmaceuticals, Inc. is most often compared with the following Healthcare names: